| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 15 | IC50 | = | 15000 | nM |
| 42 | IC50 | = | 42000 | nM |
| 8 | IC50 | = | 8000 | nM |
| 100 | IC50 | > | 100000 | nM |
| 14 | IC50 | = | 14000 | nM |
| 100 | IC50 | > | 100000 | nM |
| 100 | IC50 | > | 100000 | nM |
| 14 | IC50 | = | 14000 | nM |
| 100 | IC50 | > | 100000 | nM |
| 63 | IC50 | = | 63000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 9 | IC50 | = | 9000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 9.1 | IC50 | = | 9100 | nM |
| 30 | IC50 | < | 30000 | nM |
| 2.99 | EC50 | = | 2990 | nM |
| 1.1 | EC50 | = | 1100 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 30 | IC50 | < | 30000 | nM |
| 18.04 | EC50 | = | 18040 | nM |
| 11.2 | IC50 | = | 11200 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 0.7 | % |
| Inhibition | = | 89.8 | % |
| Inhibition | = | 6.3 | % |
| Inhibition | = | 94.8 | % |
| Inhibition | = | 2.6 | % |
| Inhibition | = | 1.1 | % |
| Inhibition | = | 2.8 | % |
| Inhibition | = | 0.6 | % |
| Inhibition | = | 1.5 | % |
| Inhibition | = | 96.5 | % |
| Inhibition | = | 79 | % |
| Inhibition | = | 93.5 | % |
| Inhibition | = | 66 | % |
| Inhibition | = | 72.8 | % |
| Inhibition | = | 91.8 | % |
| Inhibition | = | 0.7 | % |
| Inhibition | = | 82.3 | % |
| Inhibition | = | 30 | % |
| Inhibition | = | 91.9 | % |
| Inhibition | = | 84.6 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|
| Inhibition | = | 53 | % | |
| Inhibition | = | 85 | % | |
| Inhibition | = | 35 | % | |
| Inhibition | = | 33 | % | |
| Inhibition | = | 3 | % | |
| Inhibition | Not Active | |||
| Inhibition | = | 47 | % | |
| Inhibition | = | 4 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | < | 25 | % |
| Inhibition | < | 25 | % |
| Inhibition | = | 42 | % |
| Inhibition | < | 25 | % |
| Inhibition | < | 25 | % |
| Inhibition | < | 25 | % |
| Species | Strain | IsPseudotypeVirus | AssayMeth | Target | Mutations | IC50Mod | IC50 | IC50Unit | ICOtherPct | ICOtherPctUnit | ICOtherConc | ICOtherConcUnit | KiMod | Ki | KiUnit | Km | KmUnit | HostAnalog | HostAnalogSpecies | RelResFoldChgMod | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 6.2 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 5.3 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 5 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | N | standard reverse transcriptase assay | Reverse transcriptase | 50 | ug/mL | SYNTHESIS AND HIV-1 REVERSE TRANSCRIPTASE INHIBITION ACTIVITY OF 1,4-NAPHTHOQUINONE DERIVATIVES. Chemistry of Natural Compounds 2012, 47(6), 883-887. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| 3'-PROCESSING | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| HIV-1 | STRAND TRANSFER | Integrase | 0.015 | uM | 19523819 | N-(4-FLUOROBENZYL)-3-HYDROXY-9;9-DIMETHYL-4-OXO-6;7;8;9-TETRAHYDRO-4H-PYRAZINO[1;2-A]PYRIMIDINE-2-CARBOXAMIDES A NOVEL CLASS OF POTENT HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2009, 19, 4245-9. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 5.8 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ASSAY | Reverse transcriptase | 170.3 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 10.2 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ASSAY | Reverse transcriptase | 33.7 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 24.9 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | 3'-processing | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . | |||||||||||||||||||
| HIV-1 | Strand Transfer | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . | |||||||||||||||||||
| HIV-1 | 3'-processing | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 95 | % |
| Inhibition | = | 41.4 | % |
| Inhibition | = | 13.6 | % |
| Inhibition | = | 36.8 | % |
| Inhibition | = | 40.5 | % |
| Inhibition | = | 72.6 | % |
| Inhibition | = | 64.6 | % |
| Inhibition | = | 45.9 | % |
| Inhibition | = | 99.4 | % |
| Inhibition | = | 23.3 | % |
| Inhibition | = | 98.4 | % |
| Inhibition | = | 82.5 | % |
| Inhibition | = | 42.1 | % |
| Inhibition | = | 68.1 | % |
| Inhibition | = | 9.2 | % |
| Inhibition | = | 50.8 | % |
| Inhibition | = | 21.3 | % |
| Inhibition | = | 50.9 | % |
| Inhibition | = | 34.9 | % |
| Inhibition | = | 54.8 | % |
| Species | Strain | IsPseudotypeVirus | AssayMeth | CellType | CellType2 | Target | Mutations | EC50Mod | EC50 | EC50Unit | ECOtherPct | ECOtherPctUnit | ECOtherConc | ECOtherConcUnit | ToxAssayMeth | ToxCellType | CC50Mod | CC50 | CC50Unit | TIMod | TI | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-1 | LAI | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 76.74 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 69 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| R5; CLINICAL ISOLATE | 1(JSL) | P24 | PBMC | Reverse transcriptase | MDR | 0.07 | uM | 90 | % | 1 | uM | MTT | > | 100 | uM | > | 1428 | HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN | 15280474 | SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662. | ECOtherConcMod:> | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | LAV | RT | U1(THF-.alpha. STIM) | U1 | Tumor necrosis factor alpha | ~ | 30 | ug/mL | 70 | % | 50 | ug/mL | > | 50 | ug/mL | > | 1.66 | CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE | 8327469 | THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 75 | % | 10 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 38 | % | 2 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 99 | % | 50 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | IIIB | RT | HT4(R116; AZT RESISTANT CELLS) | HT4 | Reverse transcriptase | ~ | 0.01 | uM | 70 | % | 0.01 | uM | ~` | 1 | uM | ~ | 100 | FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES | 8827211 | USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968. | ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.1 | uM | 52 | % | 0.1 | uM | TRYPAN BLUE | > | 100 | uM | > | 1000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 78 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | IIIB | SYNCYT FORM | MOLT-4/H9(HIV-1(IIIB)) | MOLT-4 | gp120 | < | 1 | uM | 95 | % | 10 | uM | -100 | 10 | uM | > | 10 | CHRONICALLY INFECTED H9 CELLS | 9343823 | TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724. | CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 75 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.25 | uM | 95 | % | 0.25 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 80 | IN THE PRESENCE OF 50% NHS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.103 | uM | 95 | % | 0.103 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 194 | IN THE PRESENCE OF 10% FBS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | NL4-3 | RT | MT-4 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | WST-8 | > | 1 | uM | > | 1 | MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION | 15371436 | POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063. | ||||||
| HIV-1 | LAI | RT | HuT 78 | Reverse transcriptase | < | 1 | uM | 57.14 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 87.8 | % |
| Activity | = | 81.5 | % |
| Activity | = | 85.2 | % |
| Activity | = | 77.2 | % |
| Activity | = | 69.9 | % |
| Activity | = | 84.9 | % |
| Activity | = | 79.5 | % |
| Activity | = | 52.5 | % |
| Activity | = | 85.7 | % |
| Activity | = | 79.9 | % |
| Activity | = | 87.4 | % |
| Activity | = | 87.1 | % |
| Activity | = | 79.9 | % |
| Activity | = | 58.3 | % |
| Activity | = | 88.1 | % |
| Activity | = | 85.4 | % |
| Activity | = | 88.8 | % |
| Activity | = | 58.8 | % |
| Activity | = | 86.5 | % |
| Activity | = | 69.3 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 22 | IC50 | = | 22000 | nM |
| 100 | IC50 | > | 100000 | nM |
| 100 | IC50 | > | 100000 | nM |
| 19.5 | IC50 | = | 19500 | nM |
| 5.8 | IC50 | = | 5800 | nM |
| 100 | IC50 | > | 100000 | nM |
| 6 | IC50 | = | 6000 | nM |
| 8.2 | IC50 | = | 8200 | nM |
| 8 | IC50 | = | 8000 | nM |
| 2.3 | IC50 | = | 2300 | nM |
| 9.9 | IC50 | = | 9900 | nM |
| 6.4 | IC50 | = | 6400 | nM |
| 37.8 | IC50 | = | 37800 | nM |
| 4.4 | IC50 | = | 4400 | nM |
| 5.6 | IC50 | = | 5600 | nM |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Activity | = | 0 |
| Activity | = | 55.2 |
| Activity | = | 0 |
| Activity | = | 0 |
| Activity | = | 0 |
| Activity | = | 41 |
| Activity | = | 0 |
| Activity | = | 6.8 |
| Activity | = | 0 |
| Activity | = | 10.6 |
| Activity | = | 0 |
| Activity | = | 0 |
| Activity | = | 1.2 |
| Activity | = | 0 |
| Activity | = | 0 |
| Activity | = | 0 |
| Activity | = | 0 |
| Activity | = | 39 |
| Activity | = | 38.5 |
| Activity | = | 0 |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 12.6 | IC50 | = | 12600 | nM | |
| 35.3 | IC50 | = | 35300 | nM | |
| 31.6 | IC50 | = | 31600 | nM | |
| 0.03 | IC50 | = | 30 | nM | |
| 4.3 | IC50 | = | 4300 | nM | |
| 14 | IC50 | = | 14000 | nM | |
| 14.1 | IC50 | = | 14100 | nM | |
| 75.9 | IC50 | = | 75900 | nM | |
| 11.3 | IC50 | = | 11300 | nM | |
| 35.6 | IC50 | = | 35600 | nM | |
| 22.3 | IC50 | = | 22300 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 0 | % |
| Inhibition | = | 0 | % |
| Inhibition | = | 85.5 | % |
| Inhibition | = | 47.8 | % |
| Inhibition | = | 66.9 | % |
| Inhibition | = | 17.8 | % |
| Inhibition | = | 50.2 | % |
| Inhibition | = | 15.4 | % |
| Inhibition | = | 0 | % |
| Inhibition | = | 67.3 | % |
| Inhibition | = | 100 | % |
| Inhibition | = | 0.5 | % |
| Inhibition | = | 32.1 | % |
| Inhibition | = | 47.7 | % |
| Inhibition | = | 0 | % |
| Inhibition | = | 98.5 | % |
| Inhibition | = | 95 | % |
| Inhibition | = | 49 | % |
| Inhibition | = | 82.9 | % |
| Inhibition | = | 22 | % |
| Phenotype | Potency | Efficacy | Analysis Comment | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.0000000311 uM | Activity at 0.0000000880 uM | Activity at 0.0000001756 uM | Activity at 0.0000004972 uM | Activity at 0.0000014063 uM | Activity at 0.0000028127 uM | Activity at 0.0000079555 uM | Activity at 0.0000225014 uM | Activity at 0.0000450029 uM | Activity at 0.0001299230 uM | Activity at 0.0003002708 uM | Activity at 0.0008965874 uM | Activity at 0.00268 uM | Activity at 0.00700 uM | Activity at 0.016 uM | Activity at 0.032 uM | Activity at 0.076 uM | Activity at 0.219 uM | Activity at 0.631 uM | Activity at 1.728 uM | Activity at 3.886 uM | Activity at 8.589 uM | Activity at 17.80 uM | Activity at 49.20 uM | Activity at 107.3 uM | Activity at 231.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 0 | 4.9549 | 0.4153 | -14.5146 | 1 | 4 | 0 0 0 0 1 | 4.685 | -8.5335 | 0.7807 | 11.3474 | -12.5122 | 4.685 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Activator | 12.5893 | 29.2705 | 0 | Single point of activity | -4.9 | 4.9549 | 0.9612 | 31 | 1.7295 | 3 | 0 0 0 0 0 | 30.9001 | -1.4754 | 1.0166 | 5.6243 | 6.6083 | 30.9001 | QC'd by "Microsource" | ||||||||||||||||||||||
| Activator | 8.9125 | 65.9699 | 0 | Partial curve; partial efficacy | -5.05 | 0.6 | 0.9478 | 60.7629 | -5.207 | 2.2 | 0 0 0 0 0 | 46.0767 | -2.3225 | 0.7459 | 18.7564 | 22.5194 | 46.0767 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.3508 | -5.4241 | 12 | 4 | 0 0 0 0 0 | 2.824 | 6.9985 | -6.3081 | -17.4367 | -1.0266 | 2.824 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Inactive | 0 | 4.095 | 0.8518 | -20.6942 | -4.8432 | 4 | 1 0 0 0 0 | -16.9639 | -25.916 | -5.286 | -19.6983 | -24.7451 | -16.9639 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.8518 | -16.2964 | 1.5 | 4 | 0 0 0 0 1 | 4.1206 | 1.8961 | -0.6171 | -21.497 | -11.4248 | 4.1206 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Activator | 2.2387 | 83.6659 | 0 | Partial curve; partial efficacy; poor fit | -5.65 | 0.5 | 0.8806 | 54.0974 | -29.5685 | 2.4 | 0 0 0 0 0 | 44.3794 | -19.3312 | -4.1329 | 18.8496 | 13.5792 | 44.3794 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inhibitor | 12.5893 | 81.1747 | 42 | Partial curve; high efficacy | -4.9 | 4.095 | 0.9407 | -88.2352 | -7.0605 | -2.1 | 0 0 0 0 0 | -88.059 | -2.1141 | 2.5457 | -21.0606 | -24.383 | -88.059 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inactive | 0 | 0.8 | 0.9754 | 0.5 | 18 | 4 | 0 0 0 0 0 | 0.1686 | 15.5939 | 9.5523 | 5.2389 | 3.3969 | 0.1686 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.516 | 14 | -11.1922 | 4 | 0 0 0 0 0 | 8.9233 | 2.0681 | -9.5798 | -21.4101 | -15.067 | 8.9233 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Inhibitor | 10 | 111.4578 | 10 | Partial curve; high efficacy; poor fit | -5 | 4.095 | 0.8557 | -88.0204 | 23.4373 | -2.3 | 0 0 0 0 0 | -86.963 | 0.1371 | 16.1149 | 55.0816 | -24.8092 | -86.963 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inhibitor | 12.5893 | 111.8609 | 10 | Single point of activity | -4.9 | 1.3987 | 0.9539 | -66.6934 | 45.1675 | -3 | 0 0 0 0 0 | -51.9056 | 34.8895 | 58.2591 | 32.624 | 3.3045 | -51.9056 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inactive | 0 | 4 | 9.4501 | 23.4721 | 50.1914 | -0.8776 | 27.4967 | 9.4501 | QC'd by "Microsource" | |||||||||||||||||||||||||||||||
| Inactive | 0 | 3.6272 | 0.9908 | -9.6077 | 22.5 | 4 | 0 0 0 0 0 | -9.2564 | 21.9907 | 20.6042 | 24.2232 | 8.6092 | -9.2564 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Activator | 0 | Single point of activity | 4.9549 | 0.3547 | 25.2512 | 5 | 3 | 0 0 0 0 1 | 15.4142 | 5.7176 | 6.5342 | 43.2316 | 7.0919 | 15.4142 | QC'd by "Microsource" | |||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.6074 | 7 | 18.5 | 4 | 0 0 0 0 0 | 11.6515 | 12.5897 | 21.5938 | 21.2209 | 4.3118 | 11.6515 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Activator | 2.2387 | 52.7895 | 0 | Partial curve; partial efficacy | -5.65 | 2.2526 | 0.9613 | 44.2358 | -8.5537 | 2.2 | 0 0 0 0 1 | -9.4264 | -2.4981 | -13.182 | 11.9591 | 42.1127 | -9.4264 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.942 | 28 | 1.1909 | 4 | 0 0 0 0 1 | 1.5316 | 4.6729 | 1.2372 | -2.341 | 24.4478 | 1.5316 | QC'd by "Microsource" | ||||||||||||||||||||||||||
| Inhibitor | 35.4813 | 55.7622 | 10 | Single point of activity | -4.45 | 4.9549 | 0.7876 | -42.7915 | 12.9707 | -3 | 0 0 0 0 0 | -30.6839 | 14.5151 | 3.8713 | 4.7738 | 29.0235 | -30.6839 | QC'd by "Microsource" | ||||||||||||||||||||||
| Inhibitor | 35.4813 | 49.2317 | 10 | Single point of activity | -4.45 | 4.4495 | 0.7066 | -51.9324 | -2.7008 | -3 | 0 0 0 0 0 | -40.193 | -17.9891 | 11.8148 | -5.5992 | 0.7455 | -40.193 | QC'd by "Microsource" |
| Phenotype | Potency | Efficacy | Analysis Comment | Activity_Score | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.0000000311 uM | Activity at 0.0000000880 uM | Activity at 0.0000001756 uM | Activity at 0.0000004972 uM | Activity at 0.0000014063 uM | Activity at 0.0000028127 uM | Activity at 0.0000079555 uM | Activity at 0.0000225014 uM | Activity at 0.0000450029 uM | Activity at 0.0001299230 uM | Activity at 0.0003002708 uM | Activity at 0.0008965874 uM | Activity at 0.00268 uM | Activity at 0.00700 uM | Activity at 0.016 uM | Activity at 0.032 uM | Activity at 0.076 uM | Activity at 0.219 uM | Activity at 0.631 uM | Activity at 1.728 uM | Activity at 3.886 uM | Activity at 8.587 uM | Activity at 17.80 uM | Activity at 49.20 uM | Activity at 107.3 uM | Activity at 231.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibitor | 25.1189 | 46.3945 | 20 | Partial curve; partial efficacy | -4.6 | 2.2526 | 0.9287 | -51.2557 | -4.8612 | -2.2 | 0 0 0 0 0 | -41.1028 | -5.7868 | -8.9838 | -1.9677 | -26.4188 | -41.1028 | QC'd by "BIOMOL" | ||||||||||||||||||||||
| Inactive | 0 | 3.5117 | 0.9435 | 10 | -4.567 | 4 | 0 0 0 0 1 | -5.6299 | -3.6518 | -3.5753 | -4.2225 | 6.795 | -5.6299 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 3.0654 | 0.9376 | 11 | -2.7695 | 4 | 0 0 0 0 1 | -2.8045 | -1.4193 | -3.1412 | -1.9048 | 7.584 | -2.8045 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.7625 | 1 | -16.7 | 4 | 0 0 0 0 | -0.288 | -12.25 | 5.019 | -2.495 | -0.288 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.8335 | 4.5 | -7.0946 | 4 | 0 0 0 0 | 3.0138 | -4.2455 | 6.6652 | 3.4342 | 3.0138 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.993 | 0.5 | -16.2895 | 4 | 0 0 0 0 1 | -17.2531 | -11.9079 | 0.4577 | 0.7459 | 0.1472 | -17.2531 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 3.0654 | 0.989 | -13.9862 | -8.1964 | 4 | 0 0 0 0 | -13.7385 | -8.6044 | -8.0804 | -9.4725 | -13.7385 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.8435 | -11.2843 | 4 | 4 | 0 0 0 0 0 | -11.9036 | 3.4878 | 5.2393 | 0.5291 | 5.9839 | -11.9036 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 0.8 | 0.7241 | 0.6 | -14.6999 | 4 | 0 0 0 0 1 | -12.1307 | -11.4165 | -6.1179 | -8.0206 | -2.8333 | -12.1307 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.8652 | 1 | -19.7041 | 4 | 0 0 0 0 0 | -4.2947 | -18.0867 | -15.9371 | 4.8395 | 2.1157 | -4.2947 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inhibitor | 14.1254 | 42.1465 | 10 | Single point of activity | -4.85 | 4.9549 | 0.8997 | -40.1465 | 2 | -3 | 0 0 0 0 0 | -41.8192 | -2.393 | 5.1804 | -2.5248 | 4.6867 | -41.8192 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.6566 | -10.2454 | 0 | 4 | 0 0 0 0 0 | -10.2045 | -4.5492 | -0.0989 | 4.6103 | -5.6017 | -10.2045 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.5279 | 3 | -11.3522 | 4 | 0 0 0 0 | 1.078 | -15.7102 | -2.9932 | -14.9547 | 1.078 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 1.6924 | 0.9123 | 0.5 | -10.147 | 4 | 0 0 0 0 | 0.4297 | -9.2892 | -3.9336 | -3.1566 | 0.4297 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 2.4064 | 0.7886 | 8 | -4.3029 | 4 | 0 0 0 0 0 | 5.7256 | -1.9822 | -4.4191 | -3.8175 | 8.0142 | 5.7256 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.997 | 5.5 | -12.076 | 4 | 0 0 0 1 | -6.5693 | -12.5633 | -7.4947 | 4.9219 | -6.5693 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.9232 | -18.4489 | -2.2837 | 4 | 0 0 0 0 | -16.2075 | -1.3456 | -4.9534 | -0.2364 | -16.2075 | QC'd by "Prestwick Chemical; Inc." | |||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.9481 | 2 | -17.5643 | 4 | 0 0 0 0 1 | -13.5121 | -12.9703 | 3.6247 | 1.4507 | 0.7522 | -13.5121 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inactive | 0 | 4.9549 | 0.5725 | -10.2193 | 7.5 | 4 | 0 0 0 0 0 | -12.7555 | 5.891 | 7.5423 | -18.5161 | 0.6587 | -12.7555 | QC'd by "Prestwick Chemical; Inc." | ||||||||||||||||||||||||||
| Inhibitor | 31.6228 | 100.7069 | 40 | Partial curve; high efficacy | -4.5 | 3.5722 | 0.9933 | -104.0783 | -3.3715 | -2.1 | 0 0 0 0 0 | -83.3961 | 0.3188 | -7.6251 | -4.9588 | -20.5702 | -83.3961 | QC'd by "BIOMOL" |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | < | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| 100 | EC50 | >= | 100000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 14.9 | IC50 | = | 14900 | nM |
| 13.1 | IC50 | = | 13100 | nM |
| 12.3 | IC50 | = | 12300 | nM |
| 7.1 | IC50 | = | 7100 | nM |
| 30.2 | IC50 | = | 30200 | nM |
| 30.5 | IC50 | = | 30500 | nM |
| 5.3 | IC50 | = | 5300 | nM |
| 2.6 | IC50 | = | 2600 | nM |
| 40 | IC50 | > | 40000 | nM |
| 5.9 | IC50 | = | 5900 | nM |
| 40 | IC50 | > | 40000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 100 | NOAEL | = | 100 | uM |
| 20 | NOAEL | = | 20 | uM |
| 20 | NOAEL | = | 20 | uM |
| 20 | NOAEL | = | 20 | uM |
| 10 | NOAEL | = | 10 | uM |
| 10 | NOAEL | = | 10 | uM |
| 80 | CC50 | = | 80000 | nM |
| 20 | NOAEL | = | 20 | uM |
| 10 | NOAEL | = | 10 | uM |
| 10 | NOAEL | = | 10 | uM |
| 53 | CC50 | = | 53000 | nM |
| Standard Type | Standard Relation | Standard Value |
|---|---|---|
| Ratio CC50/EC50 | = | 6440 |
| Ratio CC50/EC50 | = | 8 |
| Ratio CC50/EC50 | = | 9 |
| Ratio CC50/EC50 | = | 5 |
| Ratio CC50/EC50 | = | 4 |
| Ratio CC50/EC50 | = | 4 |
| Ratio CC50/EC50 | = | 7 |
| Ratio CC50/EC50 | = | 4 |
| Ratio CC50/EC50 | = | 6 |
| Ratio CC50/EC50 | = | 1 |
| Ratio CC50/EC50 | = | 5 |
| Ratio CC50/EC50 | = | 8 |
| Ratio CC50/EC50 | = | 7 |
| Phenotype | Potency | Efficacy | Analysis Comment | Curve_Description | Fit_LogAC50 | Fit_HillSlope | Fit_R2 | Fit_InfiniteActivity | Fit_ZeroActivity | Fit_CurveClass | Excluded_Points | Max_Response | Activity at 0.0003270000 uM | Activity at 0.0007732774 uM | Activity at 0.00163 uM | Activity at 0.00369 uM | Activity at 0.00818 uM | Activity at 0.020 uM | Activity at 0.030 uM | Activity at 0.047 uM | Activity at 0.101 uM | Activity at 0.151 uM | Activity at 0.243 uM | Activity at 0.477 uM | Activity at 0.759 uM | Activity at 1.287 uM | Activity at 2.393 uM | Activity at 3.818 uM | Activity at 6.336 uM | Activity at 11.99 uM | Activity at 19.37 uM | Activity at 31.37 uM | Activity at 60.11 uM | Activity at 107.2 uM | Activity at 158.4 uM | Activity at 229.0 uM | Compound QC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inactive | 4 | 0 0 0 0 0 | 1.4694 | -3.5669 | -6.235 | 2.8586 | 1.8042 | 1.4694 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -4.2631 | 8.2218 | 8.0811 | 10.2927 | -3.9947 | -4.2631 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 6.0369 | 0.3398 | -2.1048 | -8.1695 | -3.6822 | 6.0369 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | -2.0565 | 1.7294 | -3.5894 | -1.2575 | -0.5402 | -2.0565 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | 2.3149 | 1.0048 | 4.6369 | -1.9963 | -3.3543 | 2.3149 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 7.2748 | 7.1515 | 6.1372 | 1.5197 | 5.2332 | 7.2748 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 1.006 | -3.3873 | -7.786 | -9.3037 | -9.1761 | 1.006 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -0.0368 | -9.4458 | -10.5155 | -9.0065 | -12.9141 | -0.0368 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 2.6 | -7.8084 | -12.3007 | -2.0954 | -6.6887 | 2.6 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -11.4867 | -18.9051 | -17.4955 | -19.0735 | -9.6682 | -11.4867 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | -7.5605 | -17.2173 | -11.0038 | -16.5656 | -22.4025 | -7.5605 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | -7.5451 | -1.1939 | -1.3084 | -5.8268 | -5.3206 | -7.5451 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | -5.5852 | -4.3753 | -1.0046 | -3.1641 | -10.1524 | -5.5852 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 0 | 1.1172 | -6.0391 | 7.0118 | 9.0446 | 1.6533 | 1.1172 | QC'd by "Chem Div" | ||||||||||||||||||||||||||||
| Inactive | 4 | 2.3359 | 1.2518 | 1.6626 | -0.9325 | -0.9194 | 2.3359 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 | -19.5354 | 0.3984 | -4.1147 | 2.1883 | -19.5354 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | -5.6552 | -4.6769 | -1.9378 | -0.5867 | -3.224 | -5.6552 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | -11.3738 | -10.4148 | -13.8912 | -10.4252 | -7.8961 | -11.3738 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | -6.1571 | -8.7102 | -2.9113 | -5.2229 | -3.4369 | -6.1571 | QC'd by "Chem Div" | |||||||||||||||||||||||||||||
| Inactive | 4 | 0 0 0 0 1 | -7.3803 | -8.8177 | -11.1654 | -6.5301 | -15.9483 | -7.3803 | QC'd by "Chem Div" |
| Activation at 11.2 uM |
|---|
| 25.9791 |
| 24.6001 |
| 23.5536 |
| 22.7312 |
| 22.7177 |
| 22.1764 |
| 22.1331 |
| 21.3196 |
| 20.9399 |
| 20.5357 |
| 19.9724 |
| 19.7958 |
| 19.6966 |
| 19.0437 |
| 18.6511 |
| 18.5926 |
| 18.5486 |
| 18.5244 |
| 18.4073 |
| 18.3393 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| ED50 | = | 7.4 | ug ml-1 |
| ED50 | = | 6.7 | ug ml-1 |
| ED50 | = | 25 | ug ml-1 |
| ED50 | = | 13 | ug ml-1 |
| ED50 | = | 20 | ug ml-1 |
| ED50 | = | 25 | ug ml-1 |
| ED50 | = | 21 | ug ml-1 |
| ED50 | > | 100 | ug ml-1 |
| ED50 | = | 20 | ug ml-1 |
| ED50 | = | 22 | ug ml-1 |
| ED50 | = | 0.2 | ug ml-1 |
| ED50 | = | 2 | ug ml-1 |
| ED50 | = | 15 | ug ml-1 |
| ED50 | = | 13 | ug ml-1 |
| ED50 | > | 100 | ug ml-1 |
| ED50 | > | 100 | ug ml-1 |
| ED50 | > | 100 | ug ml-1 |
| ED50 | = | 2 | ug ml-1 |
| ED50 | = | 2 | ug ml-1 |
| ED50 | = | 41 | ug ml-1 |
| Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|
| Inhibition | = | 15.6 | % | |
| Inhibition | = | 0.82 | % | |
| Inhibition | = | -6.13 | % | |
| Inhibition | = | -16.21 | % | Outside typical range |
| Inhibition | = | -10.09 | % | Outside typical range |
| Inhibition | = | 18.69 | % | |
| Inhibition | = | 4.4 | % | |
| Inhibition | = | 18.4 | % | |
| Inhibition | = | -5.33 | % | |
| Inhibition | = | 9.3 | % | |
| Inhibition | = | 7.3 | % | |
| Inhibition | = | 16.37 | % | |
| Inhibition | = | 15.52 | % | |
| Inhibition | = | -3.93 | % | |
| Inhibition | = | -3.74 | % | |
| Inhibition | = | 18.08 | % | |
| Inhibition | = | 8.74 | % | |
| Inhibition | = | 14.05 | % | |
| Inhibition | = | 7.24 | % | |
| Inhibition | = | 20.18 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 10 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|
| Inhibition | = | 1.2 | % | |
| Inhibition | = | -8.73 | % | |
| Inhibition | = | 4.4 | % | |
| Inhibition | = | -5.97 | % | |
| Inhibition | = | 5.32 | % | |
| Inhibition | = | 4.03 | % | |
| Inhibition | = | 8.34 | % | |
| Inhibition | = | 4.5 | % | |
| Inhibition | = | 2.88 | % | |
| Inhibition | = | -0.7 | % | |
| Inhibition | = | 10.47 | % | |
| Inhibition | = | 6.43 | % | |
| Inhibition | = | 1.01 | % | |
| Inhibition | = | 0.02 | % | |
| Inhibition | = | 15.03 | % | |
| Inhibition | = | 6.73 | % | |
| Inhibition | = | -9.54 | % | |
| Inhibition | = | 3.9 | % | |
| Inhibition | = | 0.68 | % | |
| Inhibition | = | -0.11 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 120 | % |
| Activity | = | 101 | % |
| Activity | = | 131 | % |
| Activity | = | 92 | % |
| Activity | = | 114 | % |
| Activity | = | 81 | % |
| Activity | = | 102 | % |
| Activity | = | 125 | % |
| Activity | = | 61 | % |
| Activity | = | 23 | % |
| Activity | = | 89 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | < | 25 | % |
| Inhibition | < | 25 | % |
| Inhibition | = | 42 | % |
| Inhibition | < | 25 | % |
| Inhibition | < | 25 | % |
| Inhibition | < | 25 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Inhibition | % | Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 40 | % |
| Activity | = | 51 | % |
| Activity | = | 33 | % |
| Activity | = | 124 | % |
| Activity | = | 110 | % |
| Activity | = | 61 | % |
| Activity | = | 69 | % |
| Activity | = | 47 | % |
| Activity | = | 127 | % |
| Activity | = | 27 | % |
| Activity | = | 110 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | < | 30 | % |
| Inhibition | < | 30 | % |
| Inhibition | < | 30 | % |
| Inhibition | < | 30 | % |
| Inhibition | < | 30 | % |
| Inhibition | < | 30 | % |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Inhibition | % | Not Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 114 | % |
| Activity | = | 109 | % |
| Activity | = | 128 | % |
| Activity | = | 100 | % |
| Activity | = | 119 | % |
| Activity | = | 63 | % |
| Activity | = | 84 | % |
| Activity | = | 141 | % |
| Activity | = | 71 | % |
| Activity | = | 64 | % |
| Activity | = | 94 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Inhibition | = | 0 | % |
| Inhibition | = | 89 | % |
| Inhibition | = | 0 | % |
| Inhibition | = | 1 | % |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|
| ID50 | = | 90 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | = | 11 | ug ml-1 | |
| ID50 | = | 80 | ug ml-1 | |
| ID50 | = | 270 | ug ml-1 | |
| Activity | Not Active | |||
| ID50 | = | 35 | ug ml-1 | |
| ID50 | = | 350 | ug ml-1 | |
| ID50 | = | 11 | ug ml-1 | |
| ID50 | = | 450 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | = | 48 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | = | 7 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 | |
| ID50 | = | 300 | ug ml-1 | |
| ID50 | > | 500 | ug ml-1 |
| Inhibition at 26.1 uM |
|---|
| 1.22 |
| 1.22 |
| 1.22 |
| 1.22 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| 1.21 |
| Inhibition at 2.6 uM |
|---|
| 127.19 |
| 125.38 |
| 123.56 |
| 122.83 |
| 122.83 |
| 121.76 |
| 121.66 |
| 121.6 |
| 121.5 |
| 121.39 |
| 121.22 |
| 119.02 |
| 116.83 |
| 116.33 |
| 115.89 |
| 115.77 |
| 115.42 |
| 114.27 |
| 114.13 |
| 114.01 |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 31 | % |
| Activity | = | 44 | % |
| Activity | = | 37 | % |
| Activity | = | 80 | % |
| Activity | = | 121 | % |
| Activity | = | 56 | % |
| Activity | = | 111 | % |
| Activity | = | 39 | % |
| Activity | = | 115 | % |
| Activity | = | 13 | % |
| Activity | = | 109 | % |
| Standard Type | Activity Comment |
|---|---|
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| Activity | Non-Toxic |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 24.8 | IC50 | = | 24800 | nM | |
| 100 | IC50 | > | 100000 | nM | |
| 100 | IC50 | > | 100000 | nM | |
| 100 | IC50 | > | 100000 | nM | |
| 37.9 | IC50 | = | 37900 | nM | |
| 100 | IC50 | > | 100000 | nM | |
| 14.6 | IC50 | = | 14600 | nM | |
| 6.3 | IC50 | = | 6300 | nM | |
| 17 | IC50 | = | 17000 | nM | |
| 21.8 | IC50 | = | 21800 | nM | |
| 32.1 | IC50 | = | 32100 | nM | |
| 70.3 | IC50 | = | 70300 | nM | |
| 39.2 | IC50 | = | 39200 | nM | |
| 14.2 | IC50 | = | 14200 | nM | |
| 16.3 | IC50 | = | 16300 | nM | |
| 20.9 | IC50 | = | 20900 | nM |
| Standard Type | Standard Units | Activity Comment |
|---|---|---|
| Inhibition | % | Active |
| Inhibition | % | Active |